637334-45-3

637334-45-3 structure

Name: Ocrelizumab
Chemical Name: Ocrelizumab
CAS Number: 637334-45-3
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-12-18 20:17:15
Modify Date: 2024-01-10 07:39:45
Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1].

Name	Ocrelizumab
Synonyms	Monoclonal antibody Pro70769 Pro-70769 Pro70769 Rhumab 2H7

Description	Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1].
Related Catalog	Research Areas >> Inflammation/Immunology
References	[1]. Mulero P, et al. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025.

No Any Chemical & Physical Properties